Test Price
2,800 AED✅ Home Collection Available
CABP2 Gene (Autosomal Recessive Deafness Type 93) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – ISO 9001:2015 Certified NGS Gene Sequencing
- Premium Logistics – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM daily)
- Clinical Guidance – Telephonic Post-Test Genetic Counselling for Result Interpretation
- Insurance – Direct Billing Verification via WhatsApp: +971 5 4548 8731
- DHA Licensed Facility – Premises 105, Floor 1, Building 33, Dubai Healthcare City, License 1143
Test Overview & Methodology
This state-of-the-art genetic test employs next-generation sequencing (NGS) with clinically validated bioinformatics to screen the entire CABP2 gene for pathogenic variants associated with autosomal recessive deafness type 93 (DFNB93). It delivers a definitive molecular diagnosis for congenital or early-onset sensorineural hearing loss, enabling informed family planning and audiological management. The test is indicated for individuals with a family history of hereditary hearing loss or consanguinity.
| Feature | Our ISO‑Certified NGS Test | Standard Genotyping / Alternative Lab |
|---|---|---|
| Diagnostic Sensitivity | 99.9% (full gene sequencing) | Varies; may miss deep intronic variants |
| Technology Platform | NGS with bio‑informatics clinically validated | Sanger or limited panel |
| Turnaround Time | 3 – 4 weeks | Often 6 – 8 weeks |
| Home Collection | Cold‑chain VIP phlebotomy (8AM‑11PM) | Clinic visit only |
| ISO 9001:2015 Accreditation | ✓ Cert: INT/EGQ/2509DA/3139 | Often none |
Physician Insight & Safety Protocols
“Genetic testing for inherited hearing loss is a powerful step toward precise diagnosis and personalised care. Results must be correlated with a full audiological and clinical evaluation, and I am committed to guiding you through every stage – from sample collection to post-test counselling. Early intervention, combined with genetic counselling, can truly transform outcomes for individuals and families.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory & Exclusion Criteria
Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria:
- Active systemic infection or recent blood transfusion (may interfere with DNA quality)
- Inability to provide informed consent (minors require legal guardian)
- Patients undergoing chemotherapy that may affect leukocyte yield – consult genetic counsellor
Emergency Red Flags (seek urgent care if present):
- Sudden profound hearing loss or acute vertigo
- Severe tinnitus with neurological symptoms
- This test is for genetic predisposition; it does not address acute hearing emergencies.
Patient FAQ & Clinical Guidance
1. What is the CABP2 gene test and why is it done?
The CABP2 Genetic Test identifies mutations causing autosomal recessive deafness type 93 (DFNB93), providing a definitive genetic diagnosis for hereditary hearing loss. It is indicated for individuals with congenital or early-onset sensorineural hearing loss, especially when there is a family history or consanguinity. The result helps guide audiological management, genetic counselling, and reproductive planning.
2. How is the sample collected and what is the turnaround time?
Certified phlebotomists collect a blood sample (whole blood in EDTA) or a DNA card at your home using temperature-controlled cold-chain protocols, with results available in 3 to 4 weeks. Our ISO‑certified logistics ensure sample integrity throughout. You will be notified as soon as the report is ready for a tele‑consultation with our genetics specialist.
3. How do I pay or use insurance for this test?
Our billing team verifies direct insurance coverage with your UAE provider via WhatsApp at +971 5 4548 8731, ensuring maximum reimbursement. We handle pre‑approvals for major networks and accept out‑of‑pocket payments securely online. Contact us before booking to confirm your policy benefits.
UAE Regulatory & Data Privacy Adherence
This test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient confidentiality and data security are maintained through encrypted storage and access controls. Clinical safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA-licensed facility (License 1143) upholds the highest standards of diagnostic accuracy and ethical practice.
Clinical & Logistical Metadata
| Test Name | CABP2 Gene Sequencing (Autosomal Recessive Deafness Type 93) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) with bioinformatics |
| ICD-10-CM Code | H90.3 (Sensorineural hearing loss, bilateral) |
| LOINC Code | 83325-1 (Hearing loss gene panel) |
| DHA Facility License & Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians